Cat. No. |
Product Name |
Information |
PC-20524 |
GNE-149
ER degrader
|
GNE-149 (GNE149) is a potent, full estrogen receptor alpha (ERα) antagonist and degrader with IC50 of 0.053 nM (MCF7, ERα degradation). |
PC-20417 |
SLU-PP-1072
ERRα/γ inhibitor
|
SLU-PP-1072 is a potent, selective, dual ERRα/γ inverse agonist, inhibits ERRα- and ERRγ-dependent transcription in cotransfection assays with IC50 of 4.8 and 0.9 uM. |
PC-20415 |
GSK4716
ERRγ agonist
|
GSK4716 (GSK 4716) is a selective agonist of estrogen-related receptors ERRβ and ERRγ with EC50 of 1.3 uM (ERRγ). |
PC-20414 |
DY131
ERRγ agonist
|
DY131 (GSK 9089) is a selective agonist of the ERRβ/γ receptor with EC50 of 130 nM, does not affect the ERRα, ERα and β (IC50>30 uM). |
PC-49172 |
H3B-6545 hydrochloride
ERα antagonist
|
H3B-6545 hydrochloride is a potent, covalent antagonist of both wild-type and mutant estrogen receptor alpha (ERα), shows antiproliferative activity for ERαWT and ERαY537S overexpressing MCF7 cells with or without H524 L ESR1 mutation with low nM IC50 values. |
PC-38514 |
WAY-169916
ER inhibitor
|
WAY-169916 is an orally active pathway-selective estrogen receptor (ER) ligand, inhibiting NF-kB transcriptional activity (IC50=93 nM), but is devoid of conventional estrogenic activity. |
PC-38372 |
Rintodestrant
SERD
|
Rintodestrant (G1T48) is a potent, oral selective estrogen receptor degrader (SERD) with EC50 of 0.24 nM (ERα degradation, ICW), competitively binds to and degrades estrogen receptor (ER) and blocks ER signaling in ER-positive breast cancer cells. |
PC-73405 |
Bexirestrant
Estrogen Receptor inhibitor
|
Bexirestrant is an orally active ER-α degrader with antineoplastic effect. |
PC-72139 |
BC-N102
Estrogen Receptor inhibitor
|
BC-N102 is a first-in-class novel small molecule inhibitor for targeting oncogenic and hormonal signaling in ER-positive breast cancer. |
PC-63334 |
GDC-0927 R-form
|
GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.. |
PC-63333 |
GDC-0927 racemate
|
GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.. |
PC-60204 |
Diptoindonesin G
|
A natural compound, novel chemical probe reciprocally stabilizes ERβ and destabilizes ERα in breast cancer cells. |